Literature DB >> 17926114

Determinants of patient satisfaction with photodynamic therapy for neovascular age-related macular degeneration or polypoidal choroidal vasculopathy.

Kenji Yamashiro1,2, Akitaka Tsujikawa3, Akihiro Nishida4,5, Yasuo Kurimoto4,5.   

Abstract

PURPOSE: To evaluate the determinants of patient satisfaction with photodynamic therapy (PDT) for neovascular age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV).
METHODS: Questionnaires were mailed to 69 patients who had undergone PDT for AMD or PCV at the Kobe City General Hospital. The questionnaire considered the following parameters: subjective change in visual acuity, subjective change in the relative scotoma in central vision, subjective change in visual distortion, and patient satisfaction with PDT scored on a 100-point scale.
RESULTS: Nine patients (14%) reported their subjective visual acuity change as "significantly improved" and 21 (32%) as "slightly improved"; 18 (27%) reported "no change"; 12 (18%) reported their visual acuity as "slightly worsened"; and 6 (9%) as "significantly worsened." Subjective change in the central scotoma was reported improved in 43 patients (64%) and visual distortion had improved subjectively in 31 patients (47%). The satisfaction score was 59 +/- 25 in patients who had undergone PDT for AMD and 75 +/- 24 in those with PCV. Not only the visual acuity change but also the subjective change in central scotoma and visual distortion correlated significantly with the satisfaction score.
CONCLUSIONS: More patients who have undergone PDT for AMD or PCV perceive improvement in central scotoma and visual distortion than in visual acuity. Since these subjective changes correlated significantly with the satisfaction score, subjective change in central scotoma and visual distortion, in addition to visual acuity, should be taken into account in evaluating the benefits of PDT.

Entities:  

Mesh:

Year:  2007        PMID: 17926114     DOI: 10.1007/s10384-007-0465-y

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  18 in total

1.  Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration.

Authors:  L Arias; O Pujol; J Berniell; M Rubio; G Roca; L Castillo; E Acebes
Journal:  Br J Ophthalmol       Date:  2005-03       Impact factor: 4.638

2.  Different transitions of multifocal electroretinogram recordings between patients with age-related macular degeneration and polypoidal choroidal vasculopathy after photodynamic therapy.

Authors:  H Imai; S Honda; Y Nakanishi; H Yamamoto; Y Tsukahara; A Negi
Journal:  Br J Ophthalmol       Date:  2006-07-06       Impact factor: 4.638

3.  Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.

Authors:  Rufino M Silva; João Figueira; M Luz Cachulo; Liliane Duarte; José R Faria de Abreu; J G Cunha-Vaz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

4.  Idiopathic polypoidal choroidal vasculopathy (IPCV).

Authors:  L A Yannuzzi; J Sorenson; R F Spaide; B Lipson
Journal:  Retina       Date:  1990       Impact factor: 4.256

5.  Role of photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Nazimul Hussain; Anjli Hussain; Sundaram Natarajan
Journal:  Indian J Ophthalmol       Date:  2005-06       Impact factor: 1.848

6.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

7.  Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.

Authors:  Maddalena Quaranta; Martine Mauget-Faÿsse; Gabriel Coscas
Journal:  Am J Ophthalmol       Date:  2002-08       Impact factor: 5.258

8.  Reading ability and central visual field after photodynamic therapy.

Authors:  Ilse Krebs; Susanne Binder; Ulrike Stolba; Simon Brunner
Journal:  Ophthalmologica       Date:  2004 May-Jun       Impact factor: 3.250

9.  A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration.

Authors:  A M Armbrecht; P A Aspinall; B Dhillon
Journal:  Br J Ophthalmol       Date:  2004-10       Impact factor: 4.638

10.  Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.

Authors:  Wai-Man Chan; Dennis S C Lam; Timothy Y Y Lai; David T L Liu; Kenneth K W Li; Yi Yao; Tak-Hung Wong
Journal:  Ophthalmology       Date:  2004-08       Impact factor: 12.079

View more
  2 in total

1.  Impact of photodynamic therapy on quality of life of patients with age-related macular degeneration in Korea.

Authors:  Jinhyun Kim; Hyung Woo Kwak; Won Ki Lee; Ha Kyoung Kim
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

2.  Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Chengguo Zuo; Feng Wen; Jiaqing Li; Yan Liu; Meng Li
Journal:  Doc Ophthalmol       Date:  2009-01-31       Impact factor: 2.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.